Adinazolam: Adinazolam is a short-acting triazolobenzodiazepine originally investigated as both an anxiolytic and antidepressant but never FDA approved. In clinical trials (10-90 mg/day) it showed rapid relief of anxiety and modest antidepressant efficacy comparable to tricyclics with fewer antichol
Related pages